Subscribe to RSS
DOI: 10.1055/s-0037-1615966
A Collaborative Study to Establish the 6th International Standard for Factor VIII Concentrate
Publication History
Received
30 November 2000
Accepted after revision
02 February 2001
Publication Date:
12 December 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/200106/lookinside/thumbnails/10-1055s-0037-1615966-1.jpg)
Summary
A study was carried out to replace the 5th WHO International Standard (IS) for factor VIII concentrate, because of depletion of stocks. Two candidate concentrates (X and Y) were assayed as potential replacements against the 5th IS for FVIII concentrate, in a collaborative study involving 33 laboratories. Collaborators were asked to use the ISTH/SSC recommendations, including pre-dilution of concentrates in FVIII deficient plasma in their assays. Several laboratories performed more than one assay method and altogether there were 21 sets of assays with the one-stage method, 6 with the two-stage method and 26 with the chromogenic method. There was good agreement between laboratories using each method for the comparison of concentrates X and Y against the 5th IS, but the overall potencies by one-stage and chromogenic methods each differed by approximately 5% from the overall mean, with the chromogenic potency approximately 10% higher than the one-stage. Inter-laboratory agreement was slightly better for concentrate Y than X, and stability studies indicated that Y was more stable than X. After considering all the information, together with comments from participants and from the FVIII/FIX Subcommittee of the ISTH/SSC, candidate Y (NIBSC code [97/616]), was proposed and accepted in October, 1998, by the Expert Committee on Biological Standardisation of the World Health Organisation to be the 6th International Standard for Factor VIII Concentrate with an assigned potency of 8.5 IU/ampoule.
-
References
- 1 Bangham DR, Biggs R, Brozovic M, Denson KWE, Skegg JL. A biological standard for measurement of blood coagulation factor VIII activity. Bull WHO 1971; 45: 337-51.
- 2 Barrowcliffe TW, Kirkwood TBL. An international collaborative assay for factor VIII clotting activity. Thromb Haemost 1978; 40: 261-72.
- 3 Barrowcliffe TW, Curtis AD, Thomas DP. Standardisation of factor VIII. IV. Establishment of the 3rd international standard for factor VIII:C concentrate. Thromb Haemost 1983; 50: 697-702.
- 4 World Health Organization.. Tech Rep Ser 1990; 800: 9.
- 5 World Health Organization.. Tech Rep Ser 1995; 858: 15.
- 6 Barrowcliffe TW. Factor VIII and Factor IX Sub-committee. Recommendations for the assay of high purity factor VIII concentrates. Thromb Haemost 1993; 70 (Suppl. 05) 876-7.
- 7 Barrowcliffe TW. Standardization and Assay. Semin Thrombos Hemostas 1993; 19: 73-9.
- 8 Finney D. Statistical method in biological assay. Charles Griffin; London: 1978
- 9 Kirkwood TBL. Geometric means and measure of dispersion. Biometrics 1979; 35: 908-9.
- 10 Kirkwood TBL, Tydenham MS. Design and analysis of accelerated degradation tests for the stability of biological standards. J Biol Stand 1984; 12: 195-224.
- 11 Kirkwood TBL, Barrowcliffe TW. Discrepancy between 1-stage and 2-stage assay of factor VIII:C. Br J Haematol 1978; 40: 333-8.
- 12 Barrowcliffe TW, Kemball-Cook G, Heath AB. Proposed 5th international standard for factor VIII concentrate. NIBSC unpublished report 1994
- 13 Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 4: 634-40.
- 14 Albertengo ME, Barrowcliffe TW, Oliva L, Bevan S, Raut S. New recombinant standard for FVIII concentrate gives same results as previous plasma derived standards on a range of FVIII products. Thromb Haemost 2000; 83: 789-90.